ClinicalTrials.gg
CompletedNCT03547050REGAINUpdated Oct 6, 2023

Rolandic Epilepsy Genomewide Association International Study

An observational study in Rolandic Epilepsy, sponsored by King's College London. Completed at 13 sites in 7 countries. Open to participants aged 6 Years to 25 Years. Per ClinicalTrials.gov, last updated 2023-10-06.

Sponsored by King's College London · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Other
Enrollment
210
Ages
6 Years to 25 Years
Sex
All
01

Study summary

We have discovered a small change in the genetic code which increases the risk of the brainwave abnormality that is found in rolandic epilepsy. We now wish to confirm this using a second much larger sample of patients. We will investigate the other genetic changes that cause people with the brainwave abnormality to develop seizures, as well as problems with speech, coordination, attention and learning.

Read the detailed description

Epilepsy is a common neurological disorder affecting 1% of the population. There are over 30 types of epilepsy, some common, some rare. Most epilepsies arise in childhood and have a genetic cause. Approximately 25% of child patients have "Rolandic Epilepsy" or RE, also known as Benign Epilepsy with Centrotemporal Spikes (BECTS). RE has a complex genetic basis, probably made up of combinations of susceptibility variants in different genes. Children with RE quite often have other symptoms that affect their speech, attention, reading ability or coordination. The goal of this study is to find the genetic basis for susceptibility to seizures and associated comorbidities for RE using genomewide association approaches.

We know that RE has a genetic basis and we recently discovered the genetic cause of the EEG pattern seen in RE. The goal of REGAIN is to now find the genetic basis for susceptibility to seizures and the associated symptoms above. Our hope is to be able to improve diagnosis and understand why each child with RE is different, and perhaps point us towards new treatments that are more effective and have fewer side effects.

We will compare the genetic code of 3,000 children with RE against a similar number of people not affected by epilepsy. With the proposed large sample of participants, we will be able to pinpoint the exact changes that might lead to seizures or attention problems for example. Learning the genetic basis for these problems will deepen our understanding of the mechanisms and lead to new treatments or cures.

02

Conditions studied

  • Rolandic Epilepsy

Keywords

  • Epilepsy
  • Rolandic
  • Genetics
  • Genomewide Association Study
  • RE
  • Neurology
  • Pediatrics
03

In context

Epilepsy, Rolandic

23 studies on the registry are indexed under Epilepsy, Rolandic; 3 are open to participants now.

Browse Epilepsy, Rolandic studies →

Lead sponsor

King's College London is the lead sponsor of 524 studies on the registry; 130 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Target population is 3,000 participants with a diagnosis of Rolandic Epilepsy (1,000 UK).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of Rolandic Epilepsy in accordance with the following international criteria:

    • Age of first afebrile seizure 3-12 years
    • Seizures comprising focal sensorimotor seizures affecting the vocal tract and face, with or without involvement of the arm
    • Predominant sleep-related seizures
    • EEG interictal centro-temporal spikes with normal background
  2. Current age 6-25 years

Exclusion criteria

Exclusion Criteria:

  1. No history of focal seizure
  2. Normal EEG or abnormal background features on EEG
  3. Known structural causes (stroke, tuberous sclerosis, infection, post-infectious or metabolic)
  4. Primary diagnosis of autism or global learning disability
  5. Focal central neurological deficit on clinical exam,
  6. Unable to provide
  7. Unable to provide blood sample
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Other
Enrollment
210 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Patients diagnosed with RE

    People who meet the eligibility requirements and have been diagnosed with rolandic epilepsy.

    Other: Blood draw

  • Controls

    People without a lifetime history of seizures.

    Other: Existing samples

Interventions

  • OtherBlood draw

    Participation includes one visit for one blood draw per recruited patient. 10-20ml peripheral venous blood will be taken from the antecubital fossa. The DNA from the blood sample will then be extracted and resequenced for analysis.

  • OtherExisting samples

    Control DNA samples will be used that have been previously acquired in other studies.

06

What researchers measure

Primary outcomes

  1. Allelic association p value corrected for genome wide testing

    We will look to see if there are changes in the genetic code that cause brainwave abnormalities close to the genetic changes that we have already discovered.

    Time frame: Day 1

07

Study locations

13 sites
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Hasbro Children's Hospital
    Providence, Rhode Island 02903, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
  • Dr. Juan P. Garrahan Children's Hospital
    Buenos Aires, C 1245, Argentina
  • Hospital for Sick Kids
    Toronto, Ontario M5G 0A4, Canada
  • Aghia Sophia Children's Hospital of Athens
    Athens, 115 27, Greece
  • Sicilian Epilepsy Network
    Catania, 95124, Italy
  • Commissione Genetica Lega Italiana contro l'Epilepssia
    Roma, 00198, Italy
  • Hospital Mutua de Terrassa
    Barcelona, 08221, Spain
  • Cardiff University School of Medicine
    Cardiff, CF14 4XN, United Kingdom
  • Guy's and St Thomas' NHS Foundation Trust
    London, SE1 9HT, United Kingdom
  • King's College Hospital NHS Foundation Trust
    London, SE5 8RX, United Kingdom
  • Swansea University College of Medicine
    Swansea, SA2 8PP, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2018 to primary completion in Mar 2023, 57 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2018
First posted
Jun 6, 2018
StartActual
Jun 1, 2018
Primary completionActual
Mar 17, 2023
CompletionActual
Jun 30, 2023
Last update
Oct 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03547050
Collaborators
King's College Hospital NHS Trust, Guy's and St Thomas' NHS Foundation Trust, Cardiff University, The Hospital for Sick Children, Hospital JP Garrahan, Aghia Sophia Children's Hospital of Athens, Hospital Mutua de Terrassa, Seattle Children's Hospital, Hasbro Children's Hospital, Columbia University
Responsible party
Sponsor
First posted
Jun 6, 2018
Start date
Jun 1, 2018
Primary completion
Mar 17, 2023
Completion
Jun 30, 2023
Last update
Oct 6, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion